news
New study: ‘The Corporate Reputation of Pharma in 2014 – the Patient Perspective’
13 February 2015 | By PatientView
An independent study by PatientView...
List view / Grid view
Big Pharma
news
Experts make pharma predictions for 2015: The good, the bad and the ugly
2 February 2015 | By CPhI Worldwide
Experts from CPhI Worldwide have shared their pharma predictions for 2015, suggesting that Continuous Manufacturing and QbD will expand, with FDA becoming ‘industry tutor’. However, pharma concerns about supply chain persist...
news
Orphan drug prices facing increased scrutiny after historic year for approvals, says GlobalData analyst
21 January 2015 | By GlobalData
With the US Food and Drug Administration (FDA) approving an all-time record number of orphan drugs during 2014, the pricing of these treatments is set to come under increased scrutiny, says an analyst with research and consulting firm GlobalData...
news
Patent cliff means pharmaceutical companies will lose $65 billion by 2019, says GlobalData
11 December 2014 | By GlobalData
Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent expiries of several leading drugs, according to research and consulting firm GlobalData...
news
Munich named as top location for biotechnology and pharmaceutical industries
24 November 2014 | By BioM Biotech Cluster Development GmbH
Munich is the top location for biotechnology and pharmaceutical industries according to a new study by the Chamber of Industry and Commerce (IHK)...
news
Pharmaceutical industry doing more to improve access to medicine in developing countries; performance on some aspects lags
19 November 2014 | By The Access to Medicine Index
The world’s leading pharmaceutical companies are doing more to improve access to medicine in developing countries, with a raft of new initiatives, scale-ups and innovations over the last two years...
news
Big bio/pharma would rather ‘make than buy,’ says PharmSource
Leader in contract bio/pharma industry intelligence predicts ongoing in-house manufacture...
news
Is Big Pharma still actively engaging in outsourcing?
19 February 2014 | By Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc
Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc answers the question “From a vendor perspective, do you conclude that Big Pharma is still actively engaging in outsourcing of the activities that you have expertise in?”
